3236-47-3

Basic information

• Product Name: [4-(hydroxymethyl)cyclohexyl]methanol
• Synonyms: [4-(hydroxymethyl)cyclohexyl]methanol
• CAS NO: 3236-47-3
• Molecular Formula: C₈H₁₆O₂
• Molecular Weight: 144.21
• Mol File: 3236-47-3.mol

Chemical Properties

• Melting Point: 42-43 °C
• Boiling Point: 286.229 °C at 760 mmHg
• Flash Point: 161.111 °C
• Appearance: /
• Density: 1.004 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.471
• PKA: 14.75±0.10(Predicted)
• CAS DataBase Reference: [4-(hydroxymethyl)cyclohexyl]methanol(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(hydroxymethyl)cyclohexyl]methanol(3236-47-3)
• EPA Substance Registry System: [4-(hydroxymethyl)cyclohexyl]methanol(3236-47-3)

Safety Data

• Hazardous Substances Data: 3236-47-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
[4-(hydroxymethyl)cyclohexyl]methanol is used as a building block for the synthesis of various organic compounds. The hydroxymethyl group in this compound allows for the creation of a wide range of molecules with different properties and applications.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, [4-(hydroxymethyl)cyclohexyl]methanol is used as a key component in the production of various drugs. Its unique structure and functional groups make it an ideal candidate for the development of new pharmaceutical compounds.
Used in Fragrance and Flavor Production:
[4-(hydroxymethyl)cyclohexyl]methanol is also utilized in the fragrance and flavor industry. Its ability to form a variety of different compounds with distinct scents and tastes makes it a valuable asset in the creation of new and innovative products.
Used in Specialty Chemicals:
[4-(hydroxymethyl)cyclohexyl]methanol is used as a building block for the production of specialty chemicals, which are often used in various industrial applications. The versatility of [4-(hydroxymethyl)cyclohexyl]methanol allows for the development of unique and specialized products tailored to specific needs.

InChI:InChI=1/C8H16O2/c9-5-7-1-2-8(6-10)4-3-7/h7-10H,1-6H2/t7-,8+

Upstream product

• 3399-22-2 dimethyl 1,4-cyclohexanedicarboxylate 
• 3399-21-1 cis-dimethyl 1,4-cyclohexanedicarboxylate 
• 116076-50-7 (1,4-cis-cyclohexanediyl)bis(methylene)dimethanesultonate 
• 108-05-4 vinyl acetate 
• 105-08-8 bis-1,4-(hydroxymethyl)cyclohexane 
• 100-21-0 terephthalic acid 
• 1420954-46-6 bis((4-methylcyclohexyl)methyl) cyclohexane-1,4-dicarboxylate 
• 95623-88-4 terephthalic acid 1,4-bis(4-methylcyclohexyl)methyl ester 
• 63621-97-6 (2E,4E)-hexa-2,4-diene-1,6-diacetate 
• 1119-43-3 (E,E)-hexa-2,4-dienedioic acid dimethyl ester 
• 98837-34-4 ethyl 3-hydroxy-2-methylenebutanoate 
• 140-88-5 ethyl acrylate 
• 107550-83-4 (2E,4E)-hexa-2,4-diene-1,6-diol 
• 619-81-8 cis-cyclohexane-1,4-dicarboxylic acid 

Downstream Products

• 1004-24-6 4-methylene-1-cyclohexanemethanol 
• 37180-67-9 cis-1,4-bis-(acetylsulfanyl-methyl)-cyclohexane 
• 71707-72-7 3,5-dinitro-benzoic acid-(4-methylene-cyclohexylmethyl ester) 
• 194225-81-5 [(1S,4S)-4-[[(tert-butyldiphenylsilyl)oxy]methyl]cyclohexyl]methanol 
• 116076-50-7 (1,4-cis-cyclohexanediyl)bis(methylene)dimethanesultonate 
• 15898-77-8 (Z)-1,4-bis(bromomethyl)cyclohexane 
• 78328-73-1 cis-1,4-Bis<(amidinothio)methyl>cyclohexane dibromide 
• 78307-98-9 cis-1,4-bis(mercaptomethyl)cyclohexane 
• 175072-41-0 [4-(6-Dimethylamino-purin-9-ylmethyl)-cyclohexyl]-methanol 
• 211995-88-9 cis-4-[(Z)-3-(trimethylsilyl)prop-1-en-1-yl]cyclohexylmethyl pivaloate 
• 211995-90-3 cis-4-[(Z)-3-(trimethylsilyl)prop-1-en-1-yl]cyclohexanemethanol 
• 211995-95-8 cis-4-[(Z)-prop-1-en-1-yl]cyclohexylmethyl pivaloate 
• 211995-92-5 cis-4-[(Z)-3-(trimethylsilyl)prop-1-en-1-yl]cyclohexanecarbaldehyde 
• 211995-86-7 cis-4-(pivaloyloxymethyl)cyclohexanecarbaldehyde 

Relevant articles and documents

Production of Copolyester Monomers from Plant-Based Acrylate and Acetaldehyde

PCTA is an important copolyester that has been widely used in our daily necessities. Currently, its monomers are industrially produced from petroleum-derived xylene. To reduce the reliance on fossil energy, we herein disclose an alternative route to acces

Guanidine Derivatives: How Simple Structural Modification of Histamine H3R Antagonists Has Led to the Discovery of Potent Muscarinic M2R/M4R Antagonists

This article describes the discovery of novel potent muscarinic receptor antagonists identified during a search for more active histamine H3 receptor (H3R) ligands. The idea was to replace the flexible seven methylene linker with a semirigid 1,4-cyclohexylene or p-phenylene substituted group of the previously described histamine H3R antagonists ADS1017 and ADS1020. These simple structural modifications of the histamine H3R antagonist led to the emergence of additional pharmacological effects, some of which unexpectedly showed strong antagonist potency at muscarinic receptors. This paper reports the routes of synthesis and pharmacological characterization of guanidine derivatives, a novel chemotype of muscarinic receptor antagonists binding to the human muscarinic M2 and M4 receptors (hM2R and hM4R, respectively) in nanomolar concentration ranges. The affinities of the newly synthesized ADS10227 (1-{4-{4-{[4-(phenoxymethyl)cyclohexyl]methyl}piperazin-1-yl}but-1-yl}-1-(benzyl)guanidine) at hM2R and hM4R were 2.8 nM and 5.1 nM, respectively.

THERAPEUTIC AGENTS AND METHODS OF TREATMENT

The invention is directed towards compounds (e.g., Formula (I)), their mechanism of action, and methods of modulating proliferation activity, and methods of treating diseases and disorders using the compounds described herein (e.g., Formula (I)).

Synthesis of 1,4-Cyclohexanedimethanol, 1,4-Cyclohexanedicarboxylic Acid and 1,2-Cyclohexanedicarboxylates from Formaldehyde, Crotonaldehyde and Acrylate/Fumarate

Valuable polyester monomers and plasticizers—1,4-cyclohexanedimethanol (CHDM), 1,4-cyclohexanedicarboxylic acid (CHDA), and 1,2-cyclohexanedicarboxylates—have been prepared by a new strategy. The synthetic processes involve a proline-catalyzed formal [3+1+2] cycloaddition of formaldehyde, crotonaldehyde, and acrylate (or fumarate). CHDM is produced after a subsequent hydrogenation step over a commercially available Cu/Zn/Al catalyst and a one-pot hydrogenation/oxidation/hydrolysis process yields CHDA, whereas 1,2-cyclohexanedicarboxylate is obtained by a Pd/C-catalyzed tandem decarbonylation/hydrogenation step.

Low-pressure synthesis of cyclohexanedimethanol and derivatives

The invention is directed to a process for preparing a 1,4-disubstituted cyclohexane compound of formula (I): where A is —OH, —OR, Br, or Cl; and R is a silyl group, a hydrocarbyl group, or an acyl group having 1 to 12 carbon atoms. The process includes the steps of reacting ethylene with a (2E,4E)-hexa-2,4-diene compound to produce a 3,6-disubstituted cyclohex-1-ene compound, and hydrogenating the 3,6-disubstituted cyclohex-1-ene compound to yield the 1,4-disubstituted cyclohexane compound of formula (I).

PROCESS FOR THE PREPARATION OF 1,4-CYCLOHEXANEDIMETHANOL FROM TEREPHTHALIC ACID

Disclosed is a process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid. Terephthalic acid is esterified with (4-methylcyclohexyl)methanol and the terephthalate ester hydrogenated to 1,4-cyclohexanedimethanol in a 2-stage process. The (4-methylcyclohexyl)methanol that is formed during the hydrogenation step is recycled to the esterification reaction. Also disclosed is a method for purifying and recovering the 1,4-cyclohexanedimethanol product.

INTEGRATED PROCESS FOR THE PREPARATION OF 1,4-CYCLOHEXANEDIMETHANOL FROM TEREPHTALIC ACID

Disclosed is an integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid. Terephthalic acid is esterified with (4-methylcyclohexyl)methanol and the terephthalate ester hydro genated to 1,4-cyclohexanedimethanol in a 2-stage process. The (4-methylcyclohexyl)methanol that is formed during the hydrogenation step is recycled to the esterification reaction. Also disclosed is a method for purifying and recovering the 1,4-cyclohexanedimethanol product.

PROCESS FOR THE PREPARATION OF 1,4-CYCLOHEXANEDIMETHANOL

Disclosed is a process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid. Terephthalic acid is esterified with (4-methylcyclohexyl)methanol and the terephthalate ester hydrogenated to 1,4-cyclohexanedimethanol in a 2-stage process. The (4-methylcyclohexyl)methanol that is formed during the hydrogenation step is recycled to the esterification reaction. After removal of the (4- methylcyclohexyl)methanol from the crude hydrogenation product, the 1,4- cyclohexanedimethanol product can be recovered and purified by a phase separation and distillation.

PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN(PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to metho